Zentalis Pharmaceuticals Files 8-K on Shareholder Votes
Ticker: ZNTL · Form: 8-K · Filed: Jun 21, 2024 · CIK: 1725160
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: ZNTL
TL;DR
Zentalis had a shareholder vote on June 21st. Details TBD.
AI Summary
Zentalis Pharmaceuticals, Inc. filed an 8-K on June 21, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific details about the voting matters or outcomes, but it serves as an official notification of such events.
Why It Matters
This filing indicates that Zentalis Pharmaceuticals held a shareholder vote, which is a standard corporate governance event. The specific details of the vote are not provided in this particular filing.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure about shareholder votes and does not contain material financial or operational information.
Key Players & Entities
- Zentalis Pharmaceuticals, Inc. (company) — Registrant
- June 21, 2024 (date) — Date of report
FAQ
What specific matters were submitted to a vote of Zentalis Pharmaceuticals' security holders on June 21, 2024?
The filing states that matters were submitted to a vote of security holders, but it does not specify what those matters were.
What were the results of the shareholder vote on June 21, 2024?
The filing does not disclose the results of the shareholder vote.
Is this 8-K filing related to any specific corporate actions like mergers or acquisitions?
The filing is categorized under 'Submission of Matters to a Vote of Security Holders' and does not explicitly mention mergers or acquisitions.
Where can I find more details about the shareholder meeting and the voting items?
Further details would typically be found in the proxy statement (DEF 14A) or subsequent filings that report the outcome of the vote.
What is the significance of an 8-K filing for 'Submission of Matters to a Vote of Security Holders'?
This type of 8-K filing is used to inform the public and shareholders that a vote has taken place or will take place, fulfilling disclosure requirements under the Securities Exchange Act of 1934.
Filing Stats: 626 words · 3 min read · ~2 pages · Grade level 10.1 · Accepted 2024-06-21 17:06:27
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share ZNTL The Nasdaq Glo
Filing Documents
- zntl-20240621.htm (8-K) — 41KB
- 0001725160-24-000140.txt ( ) — 184KB
- zntl-20240621.xsd (EX-101.SCH) — 2KB
- zntl-20240621_def.xml (EX-101.DEF) — 4KB
- zntl-20240621_lab.xml (EX-101.LAB) — 26KB
- zntl-20240621_pre.xml (EX-101.PRE) — 16KB
- zntl-20240621_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 21, 2024, Zentalis Pharmaceuticals, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, a total of 66,107,445 shares of common stock were present online or represented by proxy at the meeting, representing approximately 93.09% of the Company's outstanding common stock as of the April 23, 2024 record date. The following are the voting results for the proposals considered and voted upon at the Annual Meeting, all of which were described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2024. Item 1 — Election of two Class I directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified, subject to their earlier death, resignation or removal. NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes Kimberly Blackwell, M.D. 48,055,584 12,810,370 5,241,491 Enoch Kariuki, Pharm.D. 45,008,378 15,857,576 5,241,491 Item 2 — Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 66,098,083 5,665 3,697 0
— Approval, on an advisory (non-binding) basis, the compensation of the Company's named executive officers
Item 3 — Approval, on an advisory (non-binding) basis, the compensation of the Company's named executive officers. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 36,128,130 24,729,730 8,094 5,241,491 Based on the foregoing votes, Kimberly Blackwell, M.D., and Enoch Kariuki, Pharm.D., were elected as Class I Directors and Items 2 and 3 were approved.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZENTALIS PHARMACEUTICALS, INC. Date: June 21, 2024 By: /s/ Kimberly Blackwell, M.D. Kimberly Blackwell, M.D. Chief Executive Officer